ECG:NYSEEverus Construction Group, Inc. Analysis
Data as of 2026-06-18 - not real-time
$154.25
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Everus Construction Group posted a record quarter, with revenue climbing 25% year‑over‑year and EBITDA expanding sharply, driven by both its Electrical & Mechanical and Transmission & Distribution segments. The company’s ROE of nearly 39% and operating cash flow above $290 M underscore strong profitability, yet margins remain modest (gross margin ~12%, operating margin ~7.5%). On the price side, the stock trades at $154.25, comfortably above the 20‑day SMA of $149.8 and far above the 200‑day SMA of $107.5, while the MACD line sits bullish over its signal and the RSI hovers at a neutral 54. Volume is increasing, support sits at $135 and resistance near $161, and market sentiment is in an "Extreme Greed" zone, all of which fuel short‑term bullish momentum.
However, valuation metrics tell a different story: a DCF‑derived fair value of $117 suggests the market is pricing a ~30% premium, the PE ratio of 35.3 exceeds the industry average of 31.2, and the price‑to‑book sits above 11×. Coupled with a high beta of 2.53 and 30‑day volatility of roughly 49%, the stock carries significant systematic risk. No dividend is paid, limiting income appeal. Investors should weigh the strong growth narrative against the steep valuation and elevated risk profile.
However, valuation metrics tell a different story: a DCF‑derived fair value of $117 suggests the market is pricing a ~30% premium, the PE ratio of 35.3 exceeds the industry average of 31.2, and the price‑to‑book sits above 11×. Coupled with a high beta of 2.53 and 30‑day volatility of roughly 49%, the stock carries significant systematic risk. No dividend is paid, limiting income appeal. Investors should weigh the strong growth narrative against the steep valuation and elevated risk profile.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish technical indicators (price above SMA20, bullish MACD)
- Support level at $135 provides downside cushion
- High market sentiment (Extreme Greed) may fuel short‑term buying
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Revenue growth of 25% and strong ROE suggest continued earnings expansion
- Valuation premium (price > DCF fair value) limits upside
- Elevated beta and volatility increase risk
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Overvalued relative to fundamentals (PE 35 vs industry 31, DCF gap)
- High beta (2.5) and 30‑day volatility (~49%) imply price swings
- No dividend and modest margins reduce defensive appeal
Key Metrics & Analysis
Financial Health
Revenue Growth25.40%
Profit Margin5.65%
P/E Ratio35.3
ROE38.95%
ROA11.37%
Debt/Equity52.78
P/B Ratio11.5
Op. Cash Flow$293.4M
Free Cash Flow$167.1M
Industry P/E31.2
Technical Analysis
TrendBullish
RSI54.7
Support$135.08
Resistance$160.95
MA 20$149.77
MA 50$146.25
MA 200$107.53
MACDBullish
VolumeIncreasing
Fear & Greed Index90.88
Valuation
Fair Value$117.29
Target Price$169.60
Upside/Downside9.95%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.53
Volatility49.10%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.